NHI.no
Annonse
Informasjon

Svetteplager fra armhulene

Unormalt sterk svetting plager mellom én til fem prosent av befolkningen. Målet med behandlingen er å redusere svetteproduksjonen til et akseptabelt nivå eller treffe tiltak som gjør det til å leve med.

Sterk svetting fra armhulene kan være særlig brysomt under stress.

Sist oppdatert:

13. apr. 2022

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Aksillær hyperhidrose . Referanselisten for dette dokumentet vises nedenfor

  1. Smith CC, Pariser D. Primary focal hyperhidrosis. UpToDate, last reviewed Mar 2022. Accessed Apr 2022 UpToDate
  2. Svenska Sällskapet för Dermatologi och Venereologi. Riktlinjer för handläggning av primär hyperhidros inom dermatologi och venereologi. Mars 2022. Siden besøkt 12.04.22 www.ssdv.se
  3. Henning MAS, Ibler KS, Loft I et al. Epidemiology of Hyperhidrosis in Danish Blood Donors. Acta Derm Venereol. 2021 Apr 26;101(4):adv00435. PMID: 33734420.
  4. Liu Y, Bahar R, Kalia S et al. Hyperhidrosis Prevalence and Demographical Characteristics in Dermatology Outpatients in Shanghai and Vancouver. PLoS One. 2016 Apr 22;11(4):e0153719. PMID: 27105064 PubMed
  5. Abels C, Soeberdt M, Kilic A et al. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Br J Dermatol. 2021 Aug;185(2):315-322. Epub 2021 Mar 2. PMID: 33445205 PubMed
  6. Kristensen JK, Nielsen C. Progress and lack of progress in hyperhidrosis research 2015-2020. A concise systematic review. Int J Dermatol. 2022 Feb;61(2):148-157. Epub 2021 May 26. PMID: 34080686 PubMed
  7. McConaghy JR, Fosselman D. Hyperhidrosis: Management Options. Am Fam Physician. 2018 Jun 1;97(11):729-734. PMID: 30215934 PubMed
  8. Streker M, Reuther T, Verst S, Kerscher M. Axillary hyperhidrosis--efficacy and tolerability of an aluminium chloride antiperspirant. Prospective evaluation on 20 patients with idiopathic axillary hyperhidrosis. Hautarzt. 2010 Feb. 61(2):139-44.
  9. Kouris A, et al. Quality of life and social isolation in Greek adolescents with primary focal hyperhidrosis treated with Botulinum Toxin Type A: A case series. Pediatr Dermatol 2014. doi:10.1111/pde.12480 DOI
  10. Lowe NJ, Glaser DA, Eadie N, et al, for the North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: A 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 2007; 56: 604-11. PubMed
  11. Berthin C, Maillard H. Duration of Efficacy Increases with the Repetition of Botulinum Toxin A Injections in Primary Axillary Hyperhidrosis: A 15-year Study in 117 Patients. Acta Derm Venereol. 2019 Dec 1;99(13):1237-1240. PMID: 31453629 PubMed
  12. Hong HC, Lupin M, O'Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg 2012; 38:728. PubMed
  13. Lupin M, Hong HC, OʼShaughnessy KF. Long-term efficacy and quality of life assessment for treatment of axillary hyperhidrosis with a microwave device. Dermatol Surg 2014; 40:805. PubMed
  14. Glaser DA, Galperin TA. Local procedural approaches for axillary hyperhidrosis. Dermatol Clin 2014; 32:533. PubMed
  15. Wolosker N, de Campos JR, Kauffman P, et al. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg 2012; 55: 1696-700 . PubMed
  16. Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Therapeutic options. J Am Acad Dermatol. 2019 Sep;81(3):669-680. 2019 Jan 31. PMID: 30710603 PubMed
  17. Felisberto G Jr, Maria Cataneo AJ, Cristina Cataneo D. Thoracic sympathectomy for the treatment of primary axillary hyperhidrosis: systematic review and proportional meta-analysis. Ann Med. 2021 Dec;53(1):1216-1226. PMID: 34282698 PubMed
Annonse
Annonse